The Ministry of Health has registered the seventh semaglutide drug from Russian pharmaceutical companies, an analogue of Novo Nordisk’s blockbuster Ozempiс. The new drug, Segluria, is manufactured by Russia’s R-Pharm. The manufacturer of the pharmaceutical substance is the Chinese Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. It will also produce the drug at all other stages, according to the data from the State Register of Medicines.
Segluria is a solution for subcutaneous administration and will be sold in injector pens in dosages of 0,25/0,5/1 mg.
According to the latest data reported by Tenderplan search and analytical tender management system, public procurement of semaglutide-based drugs, surged by 28% in 2024, reaching 2.3 billion rubles. This growth brings sales in the state segment closer to the actual needs of patients with type II diabetes, a group that grows by 6% annually, now numbering over 4.7 million in Russia, The analytical firm DSM Group reported that commercial sales of Ozempic analogues in Russia more than tripled in 2024, rising to 8.8 billion rubles.
Semaglutide, included in Russia’s list of vital and essential medicines, was developed by Danish company Novo Nordisk (which branded it as Ozempic) in 2012 for treating type II diabetes and has also demonstrated efficacy in obesity management.
As Big Pharma stopped marketing these type of products in Russia in 2022-2023, domestic companies were interested in the production of versions of Ozempic-like drugs. Currently, four companies sell semaglutide in Russia: Geropharm, Promomed, PSK Pharma (part of Rus Biopharm Group of Companies) and Pharmasyntez-Nord. Another registered generic version in the Russian market is produced by the Indian Jodas Expoim.
